By Colin Kellaher
Bluebird bio is shedding about a quarter of its workforce as part of a restructuring plan aimed at reducing its cash operating expenses by around 20% and enabling quarterly cash flow break-even in the second half of 2025.
Bluebird on Tuesday said it will further sharpen its focus on the commercial launches of its Lyfgenia, Zynteglo and Skysona gene therapies as it looks to attract the additional capital needed to extend its cash runway.
The Somerville, Mass., company, which has about 375 employees according to data from FactSet, said it will incur charges of about $3.7 million in cash expenditures for severance and employee termination-related costs.
Bluebird said its cash flow break-even target assumes scaling to about 40 drug product deliveries per quarter. The company said there have been 41 patient starts across its portfolio so far this year, and that it expects about 40 patient starts in the fourth quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 24, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。